Saffanat Sumra

Saffanat Sumra

Auto-generated profile, based on publicly available information

Saffanat Sumra

UCSF School of Medicine, UCSF, San Francisco, CA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2024 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
DKDaniel H Kwon
Daniel H Kwon
MSMaren T Scheuner
Maren T Scheuner
MMMarissa McPhaul
Marissa McPhaul
EHEliza Hearst
Eliza Hearst
SSSaffanat Sumra
Saffanat Sumra
JBJeff Belkora
Jeff Belkora
To better understand veterans’ decisions about germline testing, we conducted a single-site, qualitative study of 32 veterans with advanced prostate cancer. Seven days after oncologist-patient discussions about germline testing, we conducted semistructured interviews with patients to explore their decision-making process using an interview guide. Four of 14 veterans with service-connected disability benefits for prostate cancer declined germline testing for fear of losing benefits because their livelihood depended on these benefits. All 18 veterans without service-connected benefits agreed to testing. Veterans declining germline testing based on this concern can lead to suboptimal cancer care because targeted treatments that could improve their outcomes may go unrecognized. Our findings contributed to new language in the Veterans Benefits Administration Compensation and Pension Manual clarifying that genetic testing showing hereditary predisposition is insufficient to deny service-connected benefits for conditions presumed to be caused by military exposures. Clinicians should communicate this protection when counseling veterans about genetic testing.

1 March 2026 in JCO Oncology Practice
Verified
Journal Article
Closed access
DKDaniel H. Kwon
Daniel H. Kwon
MSMaren T. Scheuner
Maren T. Scheuner
MMMarissa McPhaul
Marissa McPhaul
EHEliza L. Hearst
Eliza L. Hearst
SSSaffanat Sumra
Saffanat Sumra
JBJeff Belkora
Jeff Belkora
PURPOSE: Guidelines recommend offering germline testing to patients with advanced prostate cancer (PCa) to inform treatment and personal/familial cancer risk. We asked whether veterans affairs (VA) patients made informed decisions about germline testing after informed consent discussions with oncologists. METHODS: We conducted a mixed-methods study of veterans with advanced PCa at the San Francisco VA. We audio recorded patient-oncologist germline testing discussions to assess oncologist communication concordance with National Comprehensive Cancer Network consent guidelines. Seven days afterward, we administered the Decisional Conflict Scale (DCS) and KnowGene scale to assess decisional conflict and germline testing knowledge, respectively, and interviewed veterans and caregivers to characterize decision making. We separately interviewed VA oncology and genetics providers for their perspectives on veterans' decision making. RESULTS: Among 41 participants, 35 (85%) agreed to germline testing. The mean DCS score was 25/100 (higher = greater decisional conflict); 19% had scores >37.5, which is associated with decision delay. Recordings and surveys revealed that oncologists often did not communicate, and most patients lacked knowledge about key informed consent elements, particularly about potential harms, testing outcomes, and results disclosure. Interviews with patients, caregivers, and providers identified numerous patient decisional needs (decisional conflict, inadequate knowledge, unrealistic expectations, inadequate support/resources, and complex decision); barriers to patient decision making (inadequate oncologist training/bandwidth, limited access to educational resources, insufficient oncology/genetics workforce, and paternalistic culture); and facilitators (patient-centered communication, caregiver engagement, and trust in VA). CONCLUSION: Although decisional conflict about germline testing was low, some patients made uninformed decisions and oncologists did not communicate all elements of informed consent according to guidelines. To promote patient-centered care, we recommend provider training about informed consent and shared decision making, increased oncology/genetics workforce capacity, and tailored patient-facing educational resources.

1 October 2026 in JCO Oncology Advances
Verified
Journal Article
Closed access
DKDaniel H. Kwon
Daniel H. Kwon
MSMaren T. Scheuner
Maren T. Scheuner
ACAlondra Camarena
Alondra Camarena
MMMarissa McPhaul
Marissa McPhaul
SSSaffanat Sumra
Saffanat Sumra
JBJeff Belkora
Jeff Belkora
Purpose: Informed consent is an important part of oncologist-directed germline testing in prostate cancer (PCa), but patients have knowledge gaps in the elements of informed consent. Our objective was to develop an intervention to improve informed decision making about germline testing in Veterans with advanced PCa. Materials and Methods: We followed three stages of a design thinking approach: (1) Needs Assessment, (2) Prototype Development, and (3) Iterative Refinement. We applied behavior change and implementation frameworks to data obtained from literature review, stakeholders, patient interviews, and oncologist focus groups at the San Francisco Veterans Affairs (VA) Medical Center. Results: Needs Assessment: 41 Veterans, eight caregivers, six oncologists, and two genetics providers contributed to identifying five target behaviors: (1) Patient reviews educational resources, (2) oncologist communicates informed consent elements, (3) patient asks questions during consultation, (4) patient recalls information about germline testing, and (5) patient and oncologist use shared decision making. Prototype Development: we matched behaviors to evidence-based interventions consisting of a patient decision aid, coaching for question listing and consultation audio recording, audit feedback for oncologists, and education/training for oncologists. Iterative Refinement: Eleven Veterans and three oncologists viewed the intervention favorably and endorsed its personalization to Veteran needs. Intervention facilitators included Veterans' trust in oncologists and caregiver support. Barriers included Veteran access to technology and intervention complexity. Feedback led to a simplified intervention with optional coaching and a shorter version of the decision aid. Conclusion: We developed a multilevel, tailored intervention intended to improve patient decision making about PCa germline testing that was viewed favorably by patients and oncologists. We also demonstrated the feasibility and utility of combining design thinking and implementation science principles for behavioral intervention development. Next steps include implementing and evaluating the impact of the intervention.

7 November 2026 in Journal of Surgical Research
Verified
Journal Article
Closed access
HCHannah Chay
Hannah Chay
FRFabian Ramirez
Fabian Ramirez
LFLaleh Foroutani
Laleh Foroutani
SSSaffanat Sumra
Saffanat Sumra
BZBeiqun Zhao
Beiqun Zhao